Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Mind Medicine (MindMed) Inc N.MMED.WR


Primary Symbol: MNMD Alternate Symbol(s):  N.MMED.WS | N.MMED.WA | N.MMED

Mind Medicine (MindMed) Inc. is a clinical-stage biopharmaceutical company, which is engaged in developing products to treat brain health disorders. It is developing a pipeline of product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways. This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM-120 and MM-402, the Company's product candidates. MM120, is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that it is developing for the treatment of generalized anxiety disorder (GAD). MM-120 is also being studied in a subperceptual repeat administration dosing regimen for the treatment of attention deficit hyperactivity disorder (ADHD). MM-402, also referred to as R(-)-MDMA, is the Company's form of the R-enantiomer of 3,4-methylenedioxymethampheta (MDMA), which the Company is developing for the treatment of autism spectrum disorder (ASD).


NDAQ:MNMD - Post by User

Comment by TeddyTenBagson Mar 25, 2021 11:49am
169 Views
Post# 32875465

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Price action

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Price actionLol I provide value by challenging people who throw around numbers without providing any support for it like yourself. Especially when you're clearly not an experienced investor. I challenge the pumpers who throw around numbers like the stock going to $30 in a day too. Not just the ones saying there will be downside.

You still haven't provided anything meaningful for your rationale of a $2 "target". Stock could go back to 50 cents. It's run up was purely based on hype for the sector and retail traders discovering the stock. They had no trial results released or progress made on that front since the stock blew up. Anyone trying to give a price target, be it higher or lower,  for a stock that is purely speculative at this point has nothing to back it up other than the valuation is farfetched based on fundamentals and will likely crash back down to earth. But at that point, if you're notinterested in a $1B valuation, why would you be interested in a $500M valuation?

Gilly123 wrote: My spelling is not great. What does this have to do with investing?

I started with 4k in my account in 2012 and without adding any additional funds it is now 95k. I am admittedly not an expert, and do have a lot to learn. I am satisfied with these returns.

My preference is to swing trade over weeks or months. MMEd is going to be a good investment for a lot of people given some time. Still looking at my $2.00 target (although Ill set the buy order closer to 2.2). If you havnt noticed we are inching closer to it every day.

Keep your petty insults to yourself Teddy TeaBagger, and add something useful to the message board


<< Previous
Bullboard Posts
Next >>